CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Cancer Immunotherapy: The Year in Review and a Look at the Year Ahead

    Dr. Elizabeth Jaffee highlights 2018’s advances and 2019’s potential breakthroughs in cancer treatment

    January 16, 2019| Arthur N. Brodsky, PhD
  • Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo

    Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy

    October 1, 2018| Arthur N. Brodsky, PhD
  • 30 Days of CRI Impact

    Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.

    June 1, 2018| Arthur N. Brodsky, PhD
  • AACR18 Update: Lloyd J. Old Award, Overcoming Immunotherapy Resistance, and the Importance of Dendritic Cells

    Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and…

    April 18, 2018| Arthur N. Brodsky, PhD
  • CRI Researcher Highlights New Technique to Aid Immunotherapy

    Dr. Mohammad Rashidian’s nanobodies could help improve doctors’ decisions regarding immunotherapy.

    October 26, 2017| Arthur N. Brodsky, PhD
  • Recapping Our 5th Annual Cancer Immunotherapy Month

    The 5th Annual Cancer Immunotherapy Month generated more than 6,000,000 impressions and raised over $500,000.

    July 31, 2017| Arthur N. Brodsky, PhD
  • NY-ESO-1 Identified as a Promising Vaccine Target in Ovarian Cancer Patients

    New study reveals effectiveness of immunotherapy vaccine against aggressive ovarian tumors.

    April 26, 2017| Arthur N. Brodsky, PhD
  • 2016: The Year of Cancer Immunotherapy

    New immunotherapy approvals, “Advance of the Year” recognition, and the partnerships of the future.

    December 28, 2016| Arthur N. Brodsky, PhD
Previous Page
1 2

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute